Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) (Details) - USD ($)		1 Months Ended	3 Months Ended
	Nov. 22, 2021	Dec. 31, 2023	Mar. 31, 2025	Jun. 30, 2025	Sep. 30, 2024	Dec. 11, 2023	Jun. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue				$ 22,979,000	$ 0
GSK | GSK-HSD License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial transaction price	$ 120,000,000
Milestone payment receivable							$ 30,000,000
Milestone payment receivable upon achievement of phase two and first patient dosed in phase three	100,000,000
GSK | GSK-HSD License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Commercial milestone payments at first commercial sale	190,000,000
Sales-related milestone payments	$ 590,000,000
GSK | GSK-HBV Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial transaction price		$ 2,700,000
Development milestone payments			$ 2,500,000
Contract assets				0
Deferred revenue				$ 0
GSK | GSK-HBV Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and sales milestone payments						$ 830,000,000